Abstract
The transcription factors SLUG and SOX9 have been shown to define mammary stem cell state. Similarly, epithelial–mesenchymal transition (EMT) markers (E-Cadherin, mTOR) have been shown to play a role in tumor-progression and metastatic potential in breast cancer. Finally, SOX10 is known to be expressed in breast cancer as well. The overexpressions of EMT and stem cell markers have been shown to correlate with poor overall survival. In this study, we examined whether the expression of these markers correlates with intrinsic subtypes of breast cancer and whether there is a prognostic difference in their expression-profile. We analyzed 617 breast cancer samples from two tissue micro arrays. Breast cancer samples were categorized into three groups according to hormone receptor expression and HER2-status as Luminal A/B, HER2-positive, and triple negative subgroup. Immunohistochemical expressions of SLUG, SOX9, SOX10, E-Cadherin, and mTOR were semi-quantitatively analyzed using a two-tiered and three-tiered scoring system in which cytoplasmic and nuclear stains were considered. Strong nuclear expression of SLUG was observed preferentially in triple negative but not in Luminal A/B or HER2-positive cases (24 vs. 3 and 0 %, p
| Original language | English (US) |
|---|---|
| Pages (from-to) | 45-55 |
| Number of pages | 11 |
| Journal | Breast Cancer Research and Treatment |
| Volume | 154 |
| Issue number | 1 |
| DOIs | |
| State | Published - Oct 14 2015 |
Fingerprint
Keywords
- Breast cancer
- Epithelial–mesenchymal transition
- Intrinsic subtypes
- Stem cells
ASJC Scopus subject areas
- Oncology
- Cancer Research
Cite this
Differential expression of epithelial–mesenchymal transition and stem cell markers in intrinsic subtypes of breast cancer. / Pomp, Victoria; Leo, Cornelia; Mauracher, Andrea; Korol, Dimitri; Guo, Wenjun; Varga, Zsuzsanna.
In: Breast Cancer Research and Treatment, Vol. 154, No. 1, 14.10.2015, p. 45-55.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Differential expression of epithelial–mesenchymal transition and stem cell markers in intrinsic subtypes of breast cancer
AU - Pomp, Victoria
AU - Leo, Cornelia
AU - Mauracher, Andrea
AU - Korol, Dimitri
AU - Guo, Wenjun
AU - Varga, Zsuzsanna
PY - 2015/10/14
Y1 - 2015/10/14
N2 - The transcription factors SLUG and SOX9 have been shown to define mammary stem cell state. Similarly, epithelial–mesenchymal transition (EMT) markers (E-Cadherin, mTOR) have been shown to play a role in tumor-progression and metastatic potential in breast cancer. Finally, SOX10 is known to be expressed in breast cancer as well. The overexpressions of EMT and stem cell markers have been shown to correlate with poor overall survival. In this study, we examined whether the expression of these markers correlates with intrinsic subtypes of breast cancer and whether there is a prognostic difference in their expression-profile. We analyzed 617 breast cancer samples from two tissue micro arrays. Breast cancer samples were categorized into three groups according to hormone receptor expression and HER2-status as Luminal A/B, HER2-positive, and triple negative subgroup. Immunohistochemical expressions of SLUG, SOX9, SOX10, E-Cadherin, and mTOR were semi-quantitatively analyzed using a two-tiered and three-tiered scoring system in which cytoplasmic and nuclear stains were considered. Strong nuclear expression of SLUG was observed preferentially in triple negative but not in Luminal A/B or HER2-positive cases (24 vs. 3 and 0 %, p
AB - The transcription factors SLUG and SOX9 have been shown to define mammary stem cell state. Similarly, epithelial–mesenchymal transition (EMT) markers (E-Cadherin, mTOR) have been shown to play a role in tumor-progression and metastatic potential in breast cancer. Finally, SOX10 is known to be expressed in breast cancer as well. The overexpressions of EMT and stem cell markers have been shown to correlate with poor overall survival. In this study, we examined whether the expression of these markers correlates with intrinsic subtypes of breast cancer and whether there is a prognostic difference in their expression-profile. We analyzed 617 breast cancer samples from two tissue micro arrays. Breast cancer samples were categorized into three groups according to hormone receptor expression and HER2-status as Luminal A/B, HER2-positive, and triple negative subgroup. Immunohistochemical expressions of SLUG, SOX9, SOX10, E-Cadherin, and mTOR were semi-quantitatively analyzed using a two-tiered and three-tiered scoring system in which cytoplasmic and nuclear stains were considered. Strong nuclear expression of SLUG was observed preferentially in triple negative but not in Luminal A/B or HER2-positive cases (24 vs. 3 and 0 %, p
KW - Breast cancer
KW - Epithelial–mesenchymal transition
KW - Intrinsic subtypes
KW - Stem cells
UR - http://www.scopus.com/inward/record.url?scp=84945449163&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84945449163&partnerID=8YFLogxK
U2 - 10.1007/s10549-015-3598-6
DO - 10.1007/s10549-015-3598-6
M3 - Article
VL - 154
SP - 45
EP - 55
JO - Breast Cancer Research and Treatment
JF - Breast Cancer Research and Treatment
SN - 0167-6806
IS - 1
ER -